Trials / Completed
CompletedNCT01689571
A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics
A Randomised, Double-blind, Placebo-controlled, Three-way Crossover Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Two Doses of Inhaled CHF6001 DPI After 9 Days of Treatment in Adult Patients With Asthma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Chiesi Farmaceutici S.p.A. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The study is designed to look at the safety, tolerability and efficacy of 2 different doses of the study drug (CHF6001, a PDE4 inhibitor) in asthmatics, when given by inhalation, once a day for 9 days. The efficacy will be evaluated by measuring the protective effect of CHF 6001 after an allergen challenge.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CHF6001 | |
| DRUG | Placebo |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2013-04-01
- Completion
- 2013-04-01
- First posted
- 2012-09-21
- Last updated
- 2017-03-30
Locations
3 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01689571. Inclusion in this directory is not an endorsement.